Shield Thera Share News (STX)

Biogens, Sage Therapeutics postpartum depression treatment approved

(Alliance News) - The US Food & Drug Administration has approved Zurzuvae, zuranolone, 50 mg for adults with postpartum depression, Sage Therapeutics PLC and Biogen Inc said in a statement.

IN BRIEF: Shield Therapeutics prescription orders up in first quarter

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Sees strong prescription growth in the second quarter and first half of 2023. Total prescriptions for second quarter increase 50% to 15,800 compared to the first quarter. In first half of 2023, total prescriptions grow to around 26,300 which exceeds total prescription volumes for all of 2022. The company says that this growth in the first half means Shield is likely to meet its 2023 goal for US Accrufer prescriptions.

UK shareholder meetings calendar - next 7 days

IN BRIEF: Shield Therapeutics pretax loss doubles despite revenue rise

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Reports revenue in the year to December 31 trebled to GBP4.5 million from GBP1.5 million a year before. Says net product revenue from sales of Accrufer in the US totalled GBP2.9 million, up from GBP0.1 million while royalty revenue from product sales in Europe reached GBP1.4 million, up from GBP0.9 million.

IN BRIEF: Shield appoints Andy Hurley as chief commercial officer

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Appoints Andy Hurley as chief commercial officer, effective from April 10.

AIM WINNERS & LOSERS: Zytronic hit by electronic component shortages

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Shield Therapeutics 2022 revenue jumps on Accrufer iron tablet sales

(Alliance News) - Shield Therapeutics PLC on Thursday said revenue in 2022 rose amid a jump in sales of its Accrufer iron tablets, also known as Feraccru.

TRADING UPDATES: Mobile Tornado loses CEO; DeepVerge revenue jumps

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Shield Therapeutics completes GBP2.6 million open offer

(Alliance News) - Shield Therapeutics PLC on Thursday said it has raised GBP2.6 million through an open offer.

UK shareholder meetings calendar - next 7 days

TRADING UPDATES: Longboat Energy extends loan for drilling programme

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Shield Therapeutics plans share offer; agrees Accrufer collaboration

(Alliance News) - Shield Therapeutics PLC on Tuesday said it plans a share offer to raise fresh funds, while it also has agreed a sales collaboration with Viatris Inc in the US for the oral therapy Accrufer.

TRADING UPDATES: Goldplat sells shares; Chill Brands starts campaigns

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

TRADING UPDATES: Gusbourne toasts vintage; Hardide supplies Leonardo

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

EARNINGS SUMMARY: Open Orphan name change; Secured Income winds down

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: